These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. Meng XW; Koh BD; Zhang JS; Flatten KS; Schneider PA; Billadeau DD; Hess AD; Smith BD; Karp JE; Kaufmann SH J Biol Chem; 2014 Jul; 289(30):20543-58. PubMed ID: 24895135 [TBL] [Abstract][Full Text] [Related]
12. Advances in the use of PARP inhibitor therapy for breast cancer. McCann KE; Hurvitz SA Drugs Context; 2018; 7():212540. PubMed ID: 30116283 [TBL] [Abstract][Full Text] [Related]
13. The role of PARP inhibitors in Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis. De Toni EN; Ziesch A; Rizzani A; Török HP; Hocke S; Lü S; Wang SC; Hucl T; Göke B; Bruns C; Gallmeier E Oncotarget; 2016 Feb; 7(8):9477-90. PubMed ID: 26843614 [TBL] [Abstract][Full Text] [Related]
15. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
16. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371 [TBL] [Abstract][Full Text] [Related]
18. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349 [TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
20. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. Antonarakis ES; Gomella LG; Petrylak DP Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]